General
Preferred name
mirdametinib
Synonyms
PD-0325901 ()
PFE-PKIS 21 ()
PD-325901 ()
PD0325901 ()
PD325901 ()
PD 0325901 ()
PFE-PKIS_21 ()
Mirdametinib (PD0325901) ()
PD 03525901 ()
PD 901 ()
P&D ID
PD006105
CAS
391210-10-9
870474-62-7
391209-97-5
Tags
available
drug
Drug indication
Breast cancer
non-small cell lung carcinoma
Drug Status
approved
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts[1][2][3].
PRICE 66
DESCRIPTION Mirdametinib (PD 0325901) is a selective and non ATP-competitive MEK inhibitor . (GtoPdb)
DESCRIPTION On February 2025, FDA approved mirdatinib to treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection (PKIDB)
DESCRIPTION Mirdametinib (PD325901) is an MEK inhibitor (IC50=0.33 nM) with selective, non-ATP-competitive, and oral activity. Mirdametinib exhibits antitumor activity by inhibiting p-ERK1/2 expression and inducing apoptosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Potent and selective autotaxin inhibitor (Tocris Bioactive Compound Library)
Cell lines
557
Organisms
1
Compound Sets
32
AdooQ Bioactive Compound Library
A10256
Axon Medchem Screening Library
1408
Cayman Chemical Bioactives
13034
ChEMBL Drugs
CHEMBL507361
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
7935
Concise Guide to Pharmacology 2019/20
7935
Concise Guide to Pharmacology 2021/22
7935
Concise Guide to Pharmacology 2023/24
7935
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB07101
DrugMAP
DM27D4J
Enamine Bioactive Compounds
EBC-11337
EU-OPENSCREEN Bioactive Compound Library
EOS100697
EUbOPEN Chemogenomics Library
EUB0000666
Guide to Pharmacology
7935
Kinase Chemogenomic Set (KCGS 08/2017, in progress)
Kinase Chemogenomic Set (KCGS)
PFE-PKIS 21
LINCS compound set
10101-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL507361
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL507361
Mcule NIBR MoA Box Subset
MCULE-1869889294
MedChem Express Bioactive Compound Library
HY-10254
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
PD-0325901
TargetMol Bioactive Compound Library
T6189
Tocris Bioactive Compound Library
4192
Welcome Trust Cancer Drugs
1060
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
482.0
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
2.47
TPSA
90.82
Fraction CSP3
0.19
Chiral centers
1.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
ERK MAPK signaling
Apoptosis
Autophagy
MAPK
MAPK/ERK Pathway
Target
MEK1, MEK2
MAP2K1
MEK1 inhibitor
Targets
MAP2K1,MAP2K2
Primary Target
MEK
MOA
Inhibitor
MEK inhibitor
Member status
member
Therapeutic Class
Anticancer Agents
Recommended Cell Concentration
100 nM
Source data